Evelyn Wang, MD
Allergy & Immunology · Highlands Ranch, CONPI 1457715823
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,220, 6.4 times the $501 reported in 2020.
Across 298 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Sanofi$865
- GSK$728
- Takeda Pharmaceuticals U.S.A., Inc.$547
- AbbVie$427
- CSL Behring$405
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,645100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $1,292 |
| Sanofi | 47 | $865 |
| GSK | 38 | $728 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $547 |
| AbbVie | 34 | $427 |
| CSL Behring | 15 | $405 |
| Novartis | 14 | $364 |
| Regeneron Healthcare Solutions, Inc. | 10 | $357 |
| Pharming Healthcare, Inc. | 6 | $341 |
| Genentech USA, Inc. | 22 | $325 |
| Amgen | 7 | $148 |
| Biocryst US Sales Co., LLC | 7 | $146 |
| Optinose US, Inc. | 6 | $120 |
| Grifols USA, LLC | 5 | $114 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $99 |
| Organon | 5 | $95 |
| Ionis Pharmaceuticals, Inc. | 2 | $77 |
| Galderma Laboratories, L.p. | 4 | $71 |
| Cycle Pharmaceuticals Inc | 2 | $46 |
| Pfizer | 2 | $33 |
| Kaleo, Inc. | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,645 in reported general payments places this provider in the 65th percentile of 89 allergy & immunology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $80,425 |
| SymbicortBudesonide/Formoterol Fumarate | 112 | $36,099 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $28,167 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 111 | $21,498 |
| Spiriva RespimatTiotropium Bromide | 18 | $13,767 |
| DuleraMometasone/Formoterol | 21 | $9,878 |
| Arnuity ElliptaFluticasone Furoate | 29 | $9,507 |
| Qvar RedihalerBeclomethasone Dipropionate | 14 | $6,931 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,506 |
| Epinephrine | 14 | $3,631 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 122 | $3,011 |
| Ipratropium Bromide | 87 | $2,963 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $2,384 |
| Ventolin HfaAlbuterol Sulfate | 11 | $2,271 |
| Azelastine Hcl | 29 | $1,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $728 | $118,099165 claims |
| AstraZenecaSymbicort | $1,292 | $36,099112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 89 allergy & immunology providers in Colorado.
Other allergy & immunology in Highlands Ranch
- Jerald KoepkeHighlands Ranch$2K
- Rohit KatialDenver$758K
- Nicole BarberisLakewood$351K
- Christopher WebberColorado Springs$350K
- Jeffrey RumbyrtLakewood$348K
- Eric CaplanColorado Springs$290K
- Eileen WangDenver$274K
- Donald LeungDenver$208K
- Robert NathanColorado Springs$130K
- Katherine McCormackLouisville$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.